UTHealth Houston named first-ever SCN2A Multidisciplinary Center by FamilieSCN2A Foundation

In recognition of its expertise in treating SCN2A-related neurological disorders, UTHealth Houston has been designated as the first SCN2A Multidisciplinary Center by the FamilieSCN2A Foundation, the largest global advocacy organization for the group of disorders.

“Stereotyped, devalued and shunned.” Experts address treating the stigma of Parkinson’s disease

Even the best treatment approaches for Parkinson’s disease are inadequate if they do not address patients’ feelings of social rejection, isolation, loneliness and other psychosocial effects of stigma, according to a report from experts specializing in Parkinson’s and other movement disorders.

American Neurological Association Publishes Research Abstracts for ANA2022, Oct. 22–25 in Chicago

Abstracts of breaking research in neurology and neuroscience, to be presented at the 2022 American Neurological Association Annual Meeting Oct. 22-25, are now available in Annals of Neurology and on the ANA2022 website.

UTHealth Houston’s UTMOVE program receives distinguished Edmond J. Safra Fellowship in Movement Disorders

UTHealth Houston’s Movement Disorders and Neurodegenerative Diseases Fellowship Training Program (UTMOVE fellowship program) has been chosen by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) as one of eight international academic centers to train a new movement disorder clinician-researcher — a neurologist with additional training and expertise in diagnosing and treating Parkinson’s and related diseases — as part of the Edmond J. Safra Fellowship in Movement Disorders Class of 2025.

Spinal Cord Stimulation Reduces Pain and Motor Symptoms in Parkinson’s Disease Patients

A team of researchers in the United States and Japan reports that spinal cord stimulation (SCS) measurably decreased pain and reduced motor symptoms of Parkinson’s disease, both as a singular therapy and as a “salvage therapy” after deep brain stimulation (DBS) therapies were ineffective.

Mount Sinai Researchers Uncover New Molecular Drivers of Parkinson’s Disease

New Approach Will Lead to a Better Understanding of Most Cases